Allogene (ALLO) Inks Deal With Arbor Bio for CRISPR Technology
https://www.zacks.com/stock/news/2240226/allogene-allo-inks-deal-with-arbor-bio-for-crispr-technology?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2240226
Mar 13, 2024 - Allogene (ALLO) intends to combine its next generation AlloCAR T platform with Arbor Biotechnologies' proprietary CRISPR gene therapy technology to develop therapies for autoimmune diseases.
0
Is Bluebird Bio Stock a Buy Now?
https://www.fool.com/investing/2024/03/13/is-bluebird-bio-stock-a-buy-now/?source=iedfolrf0000001
Mar 13, 2024 - Are you feeling brave?
0
Boundless Bio Starts $100 Million U.S. IPO Plan
https://seekingalpha.com/article/4677702-boundless-bio-starts-100-million-us-ipo-plan?source=feed_tag_ipo_analysis
Mar 12, 2024 - Boundless Bio filed for $a 100M IPO to develop DNA treatments for cancer, and its lead candidate is in Phase 1 trials. Click here to learn more about BOLD.
0
Oncology drug developer Boundless Bio files for $100M IPO
https://seekingalpha.com/news/4077787-oncology-drug-developer-boundless-bio-files-for-100m-ipo?source=feed_sector_healthcare
Mar 08, 2024 - Boundless Bio (BOLD), a developer of ecDNA-directed oncology therapeutics, has filed for a proposed $100M initial public offering. Read more here.
0
Entera Bio GAAP EPS of -$0.31 beats by $0.01
https://seekingalpha.com/news/4077759-entera-bio-gaap-eps-of-0_31-beats-0_01?source=feed_tag_israel
Mar 08, 2024 - Entera Bio beats expectations with FY 2023 GAAP EPS of -$0.31.
0
Nuvation Bio Inc. (NUVB) Is Up 25.28% in One Week: What You Should Know
https://www.zacks.com/stock/news/2238205/nuvation-bio-inc-nuvb-is-up-25-28-in-one-week-what-you-should-know?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_10-2238205
Mar 08, 2024 - Does Nuvation Bio Inc. (NUVB) have what it takes to be a top stock pick for momentum investors? Let's find out.
0
Passage Bio, Inc. (PASG) Is Up 24.26% in One Week: What You Should Know
https://www.zacks.com/stock/news/2237527/passage-bio-inc-pasg-is-up-24-26-in-one-week-what-you-should-know?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_10-2237527
Mar 07, 2024 - Does Passage Bio, Inc. (PASG) have what it takes to be a top stock pick for momentum investors? Let's find out.
0
Should You Buy Gossamer Bio (GOSS) After Golden Cross?
https://www.zacks.com/stock/news/2237343/should-you-buy-gossamer-bio-goss-after-golden-cross?cid=CS-ZC-FT-tale_of_the_tape|golden_crossover-2237343
Mar 07, 2024 - Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
0
Generation Bio Co. (GBIO) Reports Q4 Loss, Lags Revenue Estimates
https://www.zacks.com/stock/news/2236964/generation-bio-co-gbio-reports-q4-loss-lags-revenue-estimates?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_4-2236964
Mar 06, 2024 - Generation Bio Co. (GBIO) delivered earnings and revenue surprises of -29.27% and 5.64%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
0
Why Bluebird Bio Stock Dived Into the Red on Tuesday
https://www.fool.com/investing/2024/03/05/why-bluebird-bio-stock-dived-into-the-red-on-tuesd/?source=iedfolrf0000001
Mar 05, 2024 - The biotech has had a tough time of it over the past few years; a pundit's revised take on the company won't improve that situation.
0